EMA Recommends Granting a Marketing Authorisation for a Biosimilar Bevacizumab, Onbevzi
It received a positive opinion for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell carcinoma, epithelial ovarian cancer and carcinoma of the cervix